Short-term antiproteinuric effects of disease-modifying therapies for IgA nephropathy: a systematic review and Bayesian mechanism-class indirect comparison
Abstract
Abstract Purpose Several mechanistically distinct therapies now have randomized evidence in primary IgA nephropathy, but no trial has compared two active agents directly. We estimated short-term antiproteinuric effects by mechanism class and defined how far those estimates can be interpreted comparatively. Methods We searched MEDLINE/PubMed, Europe PMC, ClinicalTrials.gov and other public registries, trial supplements, protocols and statistical analysis plans through 24 June 2026. Parallel-group randomized trials in adults with biopsy-confirmed primary IgA nephropathy were eligible when a treatment-to-control urine protein-to-creatinine ratio (UPCR) geometric mean ratio (GMR) was extractable at 26–39 weeks. Effects were analysed on the log-GMR scale in a Bayesian random-effects model with mechanism class as the node. Risk of bias was assessed with RoB 2 and confidence with CINeMA. Results Ten randomized contrasts (2,036 participants) informed four mechanism classes and nine agent nodes. APRIL/BAFF-axis therapy showed the largest modelled UPCR reduction (GMR 0.50, 95% credible interval 0.44–0.56), followed by endothelin-pathway therapy (0.62, 0.54–0.71), complement inhibition (0.65, 0.55–0.77) and targeted-release corticosteroid (0.73, 0.61–0.87). Seven trials were at low risk of bias. CINeMA confidence was moderate for class-versus-control estimates and low to very low for every active-active contrast, all of which are indirect. Conclusion APRIL/BAFF-axis therapy produced…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 2,036 participants or records.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.